<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="334988">
  <stage>Registered</stage>
  <submitdate>7/01/2010</submitdate>
  <approvaldate>8/01/2010</approvaldate>
  <actrnumber>ACTRN12610000023055</actrnumber>
  <trial_identification>
    <studytitle>An Observational, Prospective Evaluation of the St Jude Medical Epic Valve</studytitle>
    <scientifictitle>This is a Multi-centre, Multi-country, Prospective, non-randomized, observational study to confirm the clinical safety and efficacy of the St. Jude Medical (SJM) Epic porcine valve (EPIC), which is indicated for the replacement of malfunctioning native or prosthetic aortic or mitral heart valves.</scientifictitle>
    <utrn />
    <trialacronym>EPIC</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Structural Valve Deterioration (SVD)</healthcondition>
    <healthcondition>Central regurgitation</healthcondition>
    <healthcondition>calcification of the valve</healthcondition>
    <healthcondition>Thrombus or Pannus formation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study aims at confirming the clinical safety and efficacy of the St Jude Medical Epic porcine valve by establishing: the adverse effect rates, clinical staus as indicated by the New York Heart Association (NYHA) functional classification and hemodynamic performance.
Once a patient has met all the inclusion/exclusion criteria and signed consent: the patients malfunctioning Aortic or Mitral valve will be removed and replaced with the SJM Epic Valve.
Participants will undergo safety tests including bloods, Echocardiogram, Hypertension etc during Enrollment, discharge, post operative visits: 6 month and 12 month.

The SJM EPIC valve is manufactured from selected porcine aortic valve cusps that have been cross-linked with glutaraldehyde solution. The Valve is suspended on a holder which is secured to the valve with sutures. Depending on the surgeon and the case a surgical procedure will generally take between 2-6hours.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective is to confirm the clinical safety and efficacy of the SJM Epic valve.

This will be assessed through the collection of: Blood tests and Echocardiograms.</outcome>
      <timepoint>12 months post implant of SJM Epic valve</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To monitor clinical adverse effect rates. This will be analysed through the collection of the safety data: histopathology reports, operative notes and physicians reported adverse events. Early rates, linearized rates and Kaplan-Meir life tables for: Hemolysis, non-structural dysfunction, paravalvular leak, structural deterioration/failure, bleeding events, embolism, endocarditis, valve thrombosis, reoperation, explant and death.</outcome>
      <timepoint>12 months post SJM Epic valve implant. Data will be collected at 6months, 12 months and when notified (at time of occurance).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To establish clinical status as indicated by NYHA functional classification</outcome>
      <timepoint>12 months post SJM Epic valve implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To establish the devices hemodynamic performance through the analysing the Echocardiogram results for the mean gradient, peak gradient, effective orifice area, cardiac output, cardiac index and performance index.</outcome>
      <timepoint>12 months post SJM Epic Valve implant.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- The patient requires replacement of the aortic and/or mitral valve
-The patient has signed a study specific informed consent agreeing to the data collection and follow-up requirements
- The patient is of legal age in host country</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Patient already has a prosthetic valve, other than an aortic and/or mitral valve being replaced at this occasion
- Patient requries replacement of tricuspid valve or pulmonary valve
- The Patient is pregnant
- The patient has acticve endocarditis
- Patient is undergoing renal dialysis
- The patient has had an acute preoperative neurological event
- the paitient is an intravenous drug abuser, alcoholic or prison inmate</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/11/2002</anticipatedstartdate>
    <actualstartdate>1/11/2002</actualstartdate>
    <anticipatedenddate>29/04/2005</anticipatedenddate>
    <actualenddate>29/04/2005</actualenddate>
    <samplesize>300</samplesize>
    <actualsamplesize>105</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>5024</postcode>
    <postcode>3065</postcode>
    <postcode>6009</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress>St Jude Medical World headquarters
One Lillehei Plaza
St. Paul, MN 55117</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St Jude Medical</fundingname>
      <fundingaddress>One Lillehei Plaza
St. Paul, MN 55117</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to provide investigators with the information necessary to carry out a clinical evaluation of the SJM Epic Valve. In doing so the study will collect information to establish the adverse effect rates, clinical status as indicated by NYHA functional classification and hemodynamic performance.</summary>
    <trialwebsite />
    <publication>none known </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Flinders Private Hospital
Bedford Park, SA 5024</ethicaddress>
      <ethicapprovaldate>14/10/2002</ethicapprovaldate>
      <hrec>176/034</hrec>
      <ethicsubmitdate>29/08/2001</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Second Floor, East Block
The Alfred Hospital
Commercial Rd 
Melbourne Vic 3004</ethicaddress>
      <ethicapprovaldate>30/10/2002</ethicapprovaldate>
      <hrec>1/02/0166</hrec>
      <ethicsubmitdate>11/10/2002</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hosptial Human Research Ethics Committee</ethicname>
      <ethicaddress>Sir Charles Gairdner Hosptial
Hospital Avenue
Nedlands WA 6009</ethicaddress>
      <ethicapprovaldate>20/11/2002</ethicapprovaldate>
      <hrec>2002-119</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Human Research Ethics Committee</ethicname>
      <ethicaddress>St Vincents Hospital Melbourne
Research Governance 
Unit PO Box 2900 
FITZROY VIC 3065</ethicaddress>
      <ethicapprovaldate>1/10/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mr</title>
      <name>Gary Jarvis</name>
      <address>St Jude Medical 
One Lillehei Plaza
St. Paul, Minnesota 55117</address>
      <phone>+1 651 490 4320</phone>
      <fax>+1 651 490 4409</fax>
      <email>gjarvis@sjm.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Gary Jarvis</name>
      <address>St Jude Medical
One Lillehei Plaza
St Paul, Minnesota 55117</address>
      <phone>+1 651 490 4320</phone>
      <fax>+1 651 490 4409</fax>
      <email>gjarvis@sjm.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jessica Andrews</name>
      <address>St Jude Medical Australia
17 Orion Rd
Lane Cove 2066 NSW</address>
      <phone>+61 2 9936 1236</phone>
      <fax>+61 2 9936 1222</fax>
      <email>jandrews04@sjm.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Yii</name>
      <address>St Vincents Hospital
41 Victoria Pde
Fitzroy VIC 3065</address>
      <phone>+61 3 9411 7111</phone>
      <fax />
      <email>michael.yii@svhm.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>